Molecular Insights into Systemic Lupus Erythematosus Pathogenesis: From Genes to Immune Signaling

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".

Deadline for manuscript submissions: closed (30 April 2025) | Viewed by 781

Special Issue Editor


E-Mail Website
Guest Editor
Institute for Rheumatic Diseases, Ashiya, Japan
Interests: systemic lupus erythematosus; pathogenesis; cause of autoimmunity

Special Issue Information

Dear Colleagues,

I am a professor of medicine whose work contributes significantly to the clarification of the pathogenesis of systemic lupus erythematosus and autoimmune diseases.

As an invited editor, I hereby invite review manuscripts on the pathogenesis of SLE, the review based on author’s direct evidence. Review articles expounding the author’s direct evidence are highly useful for and influential in scientific community because of the prohibition of critical discussions in many recent scientific journals. There is extensive indirect evidence of the pathogenesis of SLE. However, this contributes nothing to the clarification of the pathogenesis of SLE and to the progress of science and medicine. I encourage authors with direct evidence on the pathogenesis of SLE to post their review manuscripts.

Dr. Shunichi Shiozawa
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • SLE
  • pathogenesis
  • cause
  • infectious
  • TCR revision

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 7709 KiB  
Article
Increased Sensitivity to Ionizing Radiation in a Relevant Subset of Patients with Cancer and Systemic Lupus Erythematosus
by Hannah Schenker, Lukas Kuhlmann, Dorothee Kaudewitz, Barbara Schuster, Sabine Semrau, Charlotte Schmitter, Raphaela Voigt, Ricarda Merten, Hans Geinitz, Rainer Fietkau, Sebastian Böltz, Georg Schett and Luitpold V. Distel
Cells 2025, 14(8), 569; https://doi.org/10.3390/cells14080569 - 9 Apr 2025
Viewed by 351
Abstract
It has long been hypothesized that systemic lupus erythematosus (SLE) increases radiosensitivity, but recent studies have yielded mixed results. We studied individual radiosensitivity in 70 individuals with SLE using chromosomal aberrations as biomarkers of radiosensitivity. In total, 33 patients with SLE and 37 [...] Read more.
It has long been hypothesized that systemic lupus erythematosus (SLE) increases radiosensitivity, but recent studies have yielded mixed results. We studied individual radiosensitivity in 70 individuals with SLE using chromosomal aberrations as biomarkers of radiosensitivity. In total, 33 patients with SLE and 37 patients with SLE and additional oncologic diseases were compared with healthy individuals and with patients with rectal and breast cancer. Individual radiosensitivity was assessed by ex vivo irradiation of G0 blood lymphocytes followed by three-color fluorescence in situ hybridization of chromosomes 1, 2, and 4. SLE patients have slightly higher background rates of chromosomal aberrations than healthy individuals and lower rates than cancer patients. Non-oncologic SLE patients show a rate of chromosomal aberrations similar to that seen in healthy individuals. The outliers in this group, who clearly show increased radiosensitivity, fall between healthy individuals and cancer patients. Patients with SLE and cancer have significantly higher chromosome aberration rates compared to healthy individuals (p < 0.001) and patients with isolated cancer (p = 0.007) or isolated SLE (p = 0.004). The proportion of radiosensitive patients in the oncologic SLE cohort is high, with 45% of patients showing increased radiosensitivity. There is a weak association between anti-Ro-52 autoantibodies and radiosensitivity. Based on the radiosensitivity measurement, radiation dose reduction was recommended in 11 oncological SLE patients and was successfully achieved in 5 patients by up to 21% of the dose per fraction. In the oncologic SLE cohort, a substantial portion of individuals show increased radiosensitivity. Full article
Show Figures

Graphical abstract

Back to TopTop